Browsing restrictions can be lifted for a fee.
-0.45%
Maplight therapeutics, inc.
-1.64%
Avg of Sector
-0.21%
S&P500
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Maplight therapeutics, inc. (MPLT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MPLT's short-term business performance and financial health. For the latest updates on MPLT's earnings releases, visit this page regularly.
As of the end of the reporting period, Maplight therapeutics, inc. (MPLT) had total debt of 5.8M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Maplight therapeutics, inc. (MPLT) held Total Cash and Cash Equivalents of 46.94M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
According to the past four quarterly reports, Maplight therapeutics, inc. (MPLT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 87.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Maplight therapeutics, inc. (MPLT)'s Free Cash Flow (FCF) for the period is -47.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 118.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Maplight therapeutics, inc. (MPLT) has a Price-To-Earnings (PE) ratio of -5.06 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.